Previous issues

STAY CONNECTED

Number 45 November - December 2011

» [Editorial] To cut or not to cut? Why surgeons don't have all the answers » [Cover Story] Luzia Travado: improving outcomes for patients by attending to their distress » [e-Grand Round] Prognostic and predictive markers in colorectal cancer: implications for clinical management » [Best Cancer Reporter Award] Hope for me, and for others who come after: Victoria Lambert's award-winning article explores the impact of a new network of early trial centres » [Masterpiece] Redefining the role of pathology: how Giuseppe Viale embraced the new responsibilities of the molecular era » [Systems & Services] Taking the first step on the road to cancer control » [Impact Factor] An important piece of the localised prostate cancer puzzle? » [Impact Factor] Front-line therapy in lung cancer with mutations in EGFR » [Newsround] Newsround

Number 44 September - October 2011

» [Editorial] Securing quality cancer care: Governments must step up to the plate » [Cover Story] Julio Celis: bridging science and politics » [e-Grand Round] State-of-the-art treatment for advanced melanoma » [Best Cancer Reporter Award] The future of cancer, as told through the story of Renee » [Masterclass] The ESO Masterclass: where those most eager to learn meet those most willing to teach » [Masterpiece] Spread the Word » [Spotlight on...] Thirty years on, ESTRO remains focused on its vision for a cure » [Systems & Services] A minimum acceptable standard of care for every patient » [Impact Factor] Denosumab - a new option for solid tumours metastatic to bone » [Impact Factor] Perioperative therapy improves gastro-oesophageal cancer survival » [Newsround] Newsround

Number 43 July - August 2011

» [Editorial] Patients need information. Is that clear? » [Cover Story] Peter Naredi: a ‘can do’ leader for Europe’s cancer surgeons » [e-Grand Round] Decision making in the treatment of gliomas » [Cutting Edge] Beyond Survival--what should new cancer drugs have to prove and how? » [Masterpiece] For the love of the job » [Spotlight on...] Unshackling progress in the care of childhood cancers » [Focus] Think yourself better » [Impact Factor] Rituximab for follicular lymphoma: maintaining an open mind » [Impact Factor] ASTER--another flow in the diagnostic field of lung cancer? » [Newsround] Newsround

Number 42 May - June 2011

» [Editorial] Adapting services to the age of oral therapies » [Cover Story] Jean-Yves Blay: integrating translational and clinical research » [e-Grand Round] New approaches to treating gastro-oesophageal cancer » [Cutting Edge] International biobanking regulations: the promise and the pitfalls » [Masterpiece] The secret behind a successful clinical trial » [Systems & Services] Cutting unnecessary deaths from cervical cancer » [Impact Factor] Hypoxia modification with radiotherapy for bladder cancer » [Impact Factor] An 18-gene signature (ColoPrint) for colon cancer prognosis » [Newsround] Newsround

Number 41 March - April 2011

» [Editorial] A million voices against cancer » [Cover Story] Ruth Ladenstein: raising standards of care for our young patients » [e-Grand Round] Treatment of triple negative breast cancer » [Cutting Edge] Reading the signs » [Best Cancer Reporter Award] Think before you ruin your patient’s chance of parenthood » [Masterpiece] A simple doctor’s quest to improve on today’s treatments » [Spotlight on...] Where are the consensus guidelines for women with metastatic disease? » [Systems & Services] An advanced oncology degree for busy specialists across the globe » [Impact Factor] Failure of bevacizumab in early-stage colon cancer » [Impact Factor] Ultra-targeted accelerated partial breast irradiation using TARGIT – a cautionary note » [Newsround] NEWSROUND

Number 40 January - February 2011

» [Editorial] Our role in moulding the image of cancer » [Cover Story] Klaus Meier: together we can offer the best of both worlds » [e-Grand Round] Management of metastatic pancreatic cancer: current strategies and future directions » [Cutting Edge] Promoting genetic literacy: cancer control in the BRCA era » [Best Cancer Reporter Award] Desperately seeking a bone marrow match » [Masterpiece] Real compassion is about moving things forward » [Impact Factor] Gemcitabine alone or plus cisplatin for biliary tract cancer? » [Impact Factor] Molecular selection for ‘smart’ study design in lung cancer » [Newsround] NEWSROUND

Number 39 November - December 2010

» [Editorial] Fake drugs pose a threat to Europe’s cancer patients » [Cover Story] Sara Faithfull: unleashing the potential of cancer nursing » [e-Grand Round] Cancer of unknown primary: a diagnostic and therapeutic dilemma » [Cutting Edge] Therapeutic cancer vaccines – there’s a new kid on the block » [Best Cancer Reporter Award] Shining a light on nanoparticle therapy » [Masterpiece] Steadfast in Sarajevo » [Spotlight on...] The Clinical Trials Directive: can we get it right second time around? » [Impact Factor] 200 mg-m2 melphalan – the gold standard for multiple myeloma

Number 38 September - October 2010

» [Editorial] Is it safe, is it tolerable? Why not ask the patients? » [Cover Story] Angelo Di Leo: mapping the geography of breast cancer » [e-Grand Round] Neurological side-effects caused by recently approved chemotherapy drugs » [Cutting Edge] Charged particle therapy » [Best Cancer Reporter Award] Prize for journalist who tackled taboo subject of rationing cancer therapies » [Masterpiece] Putting the person back into personalised therapies: The concerns of a head and neck cancer specialist » [Impact Factor] Neoadjuvant trial design: time for a brave new world? » [Impact Factor] Are macrophages the bad guys in Hodgkin lymphoma? » [Newsround] NEWSROUND » [Patient Voice] Adopting a child after cancer

Number 37 July - August 2010

» [Editorial] Turning the World Cancer Declaration into action » [Cover Story] Serigne Magueye Gueye: an agent for change » [e-Grand Round] Pitfalls and uncommon problems in thyroid cancer management » [Cutting Edge] Grapefruit juice and St John’s Wort are just the tip of the iceberg » [Masterpiece] Yes we can treat cancer – even in the poorest countries » [Impact Factor] Chemoradiation in head-and-neck cancer — are we any closer? » [Impact Factor] Preoperative biliary drainage – better stents in specialised centres are needed » [Newsround] Newsround » [Patient Voice] When sex lives suffer

CancerWorld invites you to visit:

European School of Oncology -
ESO Established in 1982, a non-profit organisation exclusively dedicated to increasing the knowledge of health professionals in cancer care.

Euro-Arab School of Oncology - is a joint initiative between the Egyptian Ministry of Health and Population and ESO. EASO intends to enhance and support education in the oncology field in all the Arab countries.

ECPC

Europa
Donna

Europa
Uomo

EONS

SIOG

The
Challenge
Fund

SenoNetwork

CancerWorld is a pioneering initiative of the European School of Oncology financially supported through Sharing Progress in Cancer Care, a collaborative programme between ESO and Amgen, Celgene, Eisai, Eli Lilly, Genomic Health, GlaxoSmithKline, Merck Serono, Novartis, Roche and Sanofi Aventis.

Cancer World